Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prokidney (PROK) EBITDA (2022 - 2025)

Historic EBITDA for Prokidney (PROK) over the last 4 years, with Q3 2025 value amounting to -$38.5 million.

  • Prokidney's EBITDA rose 2130.56% to -$38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$171.2 million, marking a year-over-year decrease of 952.69%. This contributed to the annual value of -$183.7 million for FY2024, which is 2122.07% down from last year.
  • Latest data reveals that Prokidney reported EBITDA of -$38.5 million as of Q3 2025, which was up 2130.56% from -$39.7 million recorded in Q2 2025.
  • Prokidney's 5-year EBITDA high stood at -$20.7 million for Q2 2022, and its period low was -$66.5 million during Q1 2022.
  • Its 4-year average for EBITDA is -$40.5 million, with a median of -$40.1 million in 2024.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 3849.72% in 2023, then tumbled by 11301.53% in 2024.
  • Prokidney's EBITDA (Quarter) stood at -$30.2 million in 2022, then rose by 19.93% to -$24.2 million in 2023, then crashed by 113.02% to -$51.6 million in 2024, then increased by 25.27% to -$38.5 million in 2025.
  • Its EBITDA stands at -$38.5 million for Q3 2025, versus -$39.7 million for Q2 2025 and -$41.4 million for Q1 2025.